Prescient Therapeutics to Raise A$6.5 million Via SPP to Advance Clinical & Pre-clinical Programs

  • Jul 28, 2020 AEST
  • Team Kalkine
Prescient Therapeutics to Raise A$6.5 million Via SPP to Advance Clinical & Pre-clinical Programs

Summary

  • Prescient Therapeutics to raise ~A$6.5 million via SPP (underwritten to $4 million) to progress its clinical & pre-clinical programs along with general working capital and costs of the offer.
  • SPP will be used to advance its clinical and pre-clinical programs in both targeted and cellular therapies for developing personalised cancer strategies.
  • Recently, two Prescient assets selected by Doherty Institute for COVID-19 antiviral testing program.

Prescient Therapeutics (ASX:PTX), The ASX-listed biotechnology player developing targeted and personalised medicines for challenging cancers, announced a Share Purchase Plan (SPP) to raise nearly A$6.5 million. The Company intends to use this capital for progressing clinical and pre-clinical programs along with providing general working capital and costs of the offer.

Prescient Therapeutics has been gaining attention on the back of its outstanding June quarter during which it achieved significant milestones. The Company is developing cancer medicines by employing its cellular as well as targeted therapies; cellular therapies consist of CAR-T with OminCAR platform, and targeted therapies include two drug candidates PTX-200 and PTX-100.

During end-May, Prescient obtained two key licenses from the University of Pennsylvania and Oxford University for establishing innovative universal CAR Platform ‘OmniCAR’.

Key Details of Share Purchase Plan

The SPP is underwritten to A$4 million by Viriathus Capital Pty Ltd and was arranged by Cumulus Wealth Pty Ltd.

Under this Share Purchase Plan new fully paid ordinary shares will be issued at 5.5 cents per share, corresponding to a 15% discount to the VWAP (volume-weighted average price) over the ten trading days before the date of SPP announcement, and nearly 16% discount to the previous price.

Prescient will offer Eligible Shareholders who were registered shareholders on the record date (23 July 2020) the prospect to apply for up to A$30,000 of new fully paid ordinary shares in the Company under the SPP.

For more information on application form click here.

Key indicative dates for the SPP-

Utilisation of Funds

Prescient disclosed that the funds raised from the SPP would be employed for the progressing of its clinical and pre-clinical programs in both targeted as well as cellular therapies to develop personalised cancer strategies, general working capital including costs of the offer.

Moreover, the Company disclosed that participation in the SPP is entirely voluntary and all Shares issued under the SPP will rank equally with existing Shares and will carry similar voting rights and entitlement to receive distributions.

Under the SPP, no brokerage, commissions or other transaction costs will apply to purchases.

On this Prescient CEO and Managing Director, Steven Yatomi-Clarke stated-

Besides the SPP, on 21 July 2020, Prescient recently announced that two of its assets were selected for COVID-19 antiviral testing program by Doherty Institute on the basis of their potential antiviral properties.

To Know More, Do Read: Remarkable! Assets of Prescient Selected for COVID-19 Antiviral Testing Program by Doherty Institute

Dodging the COVID-19 turmoil, Prescient’s first half of 2020 has been immensely exhilarating, initially by obtaining key licenses for next-generation immunotherapy platform ‘OmniCAR’, subsequently with two US patents for PTX-200, and recently by joining the race of developing COVID-19 treatment.

Moreover, the latest SPP activity strengthens the balance sheet of the Company, bolstering the development of its existing endeavors.

On 27 July 2020, PTX stock quoted at A$0.057 with A$26.02 million market capitalization. 

 


Disclaimer
The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. The above article is sponsored but NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. All pictures are copyright to their respective owner(s). Kalkinemedia.com does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.

 

There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

CLICK HERE FOR YOUR FREE REPORT!
   
x
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK